"Expected Value", page-3

I don't know what more people can expect from an osteoarthritis drug, than what Zilosul offers.

I don't think there will ever be a better solution for osteoarthritis in our lifetimes. The idea that a perfect drug will come along which just wipes out pain without any adverse events, cures the disease, blitzes away your decades of wear an tear is - at this point in human history - outright fantasy.

Zilosul is pretty humble. It's not exactly glamorous, but: It is safe. It is affordable. It works for a large % of people, and it works to a higher than meaningful degree.

These are the best discoveries. The quiet achiever that is consistent, and can significantly be applied to millions and millions of people worldwide and safely. We hear about "blockbuster indications" and "the holy grail" and it's easy to brush them off as marketing BS because the drug can appear quite unassuming. Don't be fooled. If the results produced in Australian SAS patients prove out through trials and through widespread use - this drug will become THE go-to frontline treatment for this disease globally and you do not want to miss an opportunity like that.

I'm not going to tell you what I think this can return, per share including dividends, across the next 20 years - because it'd sound ridiculous. Just don't miss the opportunity to hold some, even if it's only 1,000-10,000 across that kind of timeframe. You do not want to be an ex-holder if this all plays out well.